DOCSLIB.ORG

LEGEND: Clinical Insights for Hypertension

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LEGEND: Clinical Insights for Hypertension LEGEND: Clinical insights for hypertension Patrick Ryan, Martijn Schuemie, Marc Suchard on behalf of the LEGEND team OHDSI Symposium 12 October 2018 Current knowledge base for hypertension Head-to-head antihypertensive drug comparisons co − amilozide hydralazine minoxidil guanfacine methyldopa chlorthalidone hydrochlorothiazide bendroflumethiazide clonidine indapamide metolazone terazosin benazepril prazosin captopril Driven primarily by ALLHAT doxazosin enalapril fosinopril Aliskiren I just 3 individual drugs lisinopril labetalol moexipril carvedilol perindopril pindolol Focus: efficacy safety quinapril penbutolol ramipril carteolol trandolapril acebutolol azilsartan propranolol candesartan Can LEGEND provide nadolol eprosartan irbesartan nebivolol 1. reliable – concordant w/ RCTs losartan metoprolol olmesartan bisoprolol telmisartan 2. rich – across “all” comparators betaxolol valsartan atenolol amlodipine felodipine spironolactone isradipine 3. relevant – inform practice epleronone nicardipine nifedipine triamterene nisoldipine amiloride lacidipine diltiazem torsemide furosemide verapamil evidence? bumetanide Trials: 40 N = 102 [1148] 33K − − LEGEND knowledge base for hypertension Head-to-head HTN drug comparisons co co − − amilozide amilozide hydralazine hydralazine minoxidil minoxidil guanfacine guanfacine methyldopa methyldopa chlorthalidone chlorthalidone hydrochlorothiazide hydrochlorothiazide bendroflumethiazide bendroflumethiazide clonidine indapamide clonidine indapamide metolazone metolazone terazosin terazosin benazepril benazepril prazosin captopril prazosin captopril doxazosin enalapril doxazosin enalapril fosinopril fosinopril Aliskiren Aliskiren lisinopril lisinopril labetalol labetalol moexipril moexipril carvedilol carvedilol perindopril perindopril pindolol pindolol quinapril quinapril penbutolol penbutolol ramipril ramipril carteolol carteolol trandolapril trandolapril acebutolol azilsartan acebutolol azilsartan propranolol candesartan propranolol candesartan nadolol eprosartan nadolol eprosartan irbesartan irbesartan nebivolol nebivolol losartan losartan metoprolol metoprolol olmesartan olmesartan bisoprolol bisoprolol telmisartan telmisartan betaxolol betaxolol valsartan valsartan atenolol atenolol amlodipine amlodipine felodipine felodipine spironolactone isradipine spironolactone isradipine epleronone nicardipine epleronone nicardipine nifedipine nifedipine triamterene triamterene nisoldipine nisoldipine amiloride lacidipine amiloride lacidipine diltiazem diltiazem torsemide torsemide furosemide furosemide verapamil verapamil bumetanide bumetanide Trials: 40 Comparisons: 10, 278 N = 102 [1148] 33K N = 3502 [212K] 1.9M − − − − e168 Whelton et al. JACC VOL. 71, NO. 19, 2018 2017 High Blood Pressure Clinical Practice Guideline MAY 15, 2018:e127– 248 2. The treatment of patients with hypertension without decreases CVD morbidity and mortality. The clinical elevated risk has been systematically understudied trial evidence is strongest for a target BP of 140/90 because lower-risk groupswouldrequireprolonged mm Hg in this population. However, observational follow-up to have a sufficient number of clinical events studies suggest that these individuals often have a high to provide useful information. Although there is clin- lifetime risk and would benefitfromBPcontrolearlier ical trial evidence that both drug and nondrug therapy in life (S8.1.5-19,S8.1.5-20). willFirst-line interrupt the progressive agents course of hypertension (S8.1.5-6),thereisnotrialevidencethatthistreatment 8.1.6. Choice of Initial Medication Recommendation for Choice of Initial Medication 2017References ACC/AHA that support theGuidelines recommendation are summarized in Online Data Supplement 27 and Systematic Review Report. COR LOE RECOMMENDATION 1. For initiation of antihypertensive drug therapy, first-line agents include thiazide diuretics, CCBs, and ACE SR IA inhibitors or ARBs. (S8.1.6-1,S8.1.6-2) SR indicates systematic review. “In particular, there is inadequate evidence to support the initial use of beta blockersSynopsis for hypertension in the absence of specificeffective for cardiovascular prevention of CVDcomorbidities.” than other first-step The overwhelming majority of persons with BP suffi- agents, such as thiazide diuretics (S8.1.6-3,S8.1.6-10). ciently elevated to warrant pharmacological therapy may Recommendation-SpecificSupportiveText be best treated initially with 2 agents (see Section 8.1.6.1). When initiation of pharmacological therapy with a single 1. The overall goal of treatment should be reduction in BP, 2018medication ESC/ESH is appropriate, Guidelines: primary consideration Class should I, Levelin A the context of underlying CVD risk. Five drug classes be given to comorbid conditions (e.g., HF, CKD) for which have been shown, in high-quality RCTs, to prevent CVD “Amongspecifi allcclassesofBP-loweringmedicationareindicated antihypertensive drugs, ACE inhibitors,as compared ARBs, with beta-blockers, placebo (diuretics, ACE CCBs, inhibitors, (see Section 9) (S8.1.6-1).Inthelargesthead-to-head ARBs, CCBs, and beta blockers) (S8.1.6-11,S8.1.6-12).In and [thiazide]comparison of diureticsfirst-step drug . therapy have for demonstrated hypertension effectivehead-to-head reduction comparisons of of BPfirst-step andCV therapy, events(S8.1.6-3) in RCTs,,thethiazide-typediureticchlorthalidonewas and thus are indicated as thedifferent basis drug of classesantihypertensive have been reported treat- to provide superior to the CCB amlodipine and the ACE inhibitor somewhat divergent capacity to prevent specificCVD mentlisinopril strategies.” in preventing “. beta-blockers HF,aBP-relatedoutcomeof are usuallyevents. equivalent Interpretation in preventing ofmeta-analysescomparing major CV increasing importance in the growing population of older agents from different drug classes is challenging events,persons except with hypertension for less(S8.1.6-4 effective—S8.1.6-7) prevention.Addition- of strokebecause the . relevant . ” RCTs were conducted in different ally, ACE inhibitors were less effective than thiazide di- time periods, during which concurrent antihyperten- uretics and CCBs in lowering BP and in prevention of sive therapy was less or more common, and the efficacy stroke. For black patients, ACE inhibitors were also of agents from certain drug classes may have changed. notably less effective than CCBs in preventing HF (S8.1.6- In recognition of this, some (S8.1.6-2) but not all (S8.1.6- 8) and in the prevention of stroke (S8.1.6-9) (see Section 11,S8.1.6-12) meta-analyses, as well as the largest indi- 10.1). ARBs may be better tolerated than ACE inhibitors vidual RCT that compared first-step agents (S8.1.6-3), in black patients, with less cough and angioedema, but have suggested that diuretics, especially the long-acting according to the limited available experience they offer no thiazide-type agent chlorthalidone, may provide an proven advantage over ACE inhibitors in preventing optimal choice for first-step drug therapy of hyperten- stroke or CVD in this population, making thiazide diuretics sion. In contrast, some meta-analyses have suggested (especially chlorthalidone) or CCBs the best initial choice that beta blockers may be less effective, especially for for single-drug therapy. For stroke, in the general popu- stroke prevention in older adults, but interpretation is lation, beta blockers were less effective than CCBs (36% hampered by inclusion of RCTs that used beta blockers lower risk) and thiazide diuretics (30% lower risk). CCBs that are now considered to be inferior for prevention of have been shown to be as effective as diuretics for CVD (S8.1.6-13,S8.1.6-14).Inasystematicreview reducing all CVD events other than HF, and CCBs are a and network meta-analysis conducted for the good alternative choice for initial therapy when thiazide present guideline, beta blockers were significantly diuretics are not tolerated. Alpha blockers are not used as less effective than diuretics for prevention of stroke first-line therapy for hypertension because they are less and cardiovascular events (S8.1.6-1).Diureticswerealso First-line agents: comparisons from RCTs RCT − AMI Efficacy outcomes: myocardial infarction, heart failure, stroke Figure 3.3 Network of clinical trials of antihypertensive drug classes in which myocardial infarction was reported (N=29). * ACE Target ACEIs CI overlap full ● ARBs ● ALPINE THZ partial ARB 0.41 (0.01-5.6) ● ● cBBs ● ● ● ● ● dCCBs ● ● ● ● ● ● ● ASCOT-BPLA, ELSA CCB BB TZDs ● ● ● ● 0.89 (0.55-1.5) *The trials included in each pair-wise comparison are labeled above the arrow. Summary of relative risk (RR) and 95% CIs for the direct comparisons are shown below the arrow. For each pair-wise comparison, the line starts at the reference group and points towards the comparison group. Thus, the arrowhead points to a class of antihypertensive drugs for which a higher RR would signify an increased risk of myocardial infarction. Comparator cBBs TZDs ARBs Figure 3.4. Network of clinical trials of antihypertensive drug classes in which heart failure was reported (N=21). ACEIs dCCBs © 2017 by the28 American /College 30 of Cardiology estimates Foundation and the American Heart are Association, concordant Inc. (discordant59 in BBs for HF) First-line agents: comparisons from LEGEND RCT − AMI Acute myocardial infarction Meta−analysis Efficacy outcome: myocardial infarction, heart failure, stroke RCTs LEGEND ACEIs ACEIs ARBs ARBs cBBs cBBs dCCBs dCCBs TZDs TZDs cBBs cBBs TZDs TZDs ARBs ARBs ACEIs ACEIs dCCBs dCCBs Data source:
Load more

Recommended publications
  • Table 2. 2012 AGS Beers Criteria for Potentially
    Table 2. 2012 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Strength of Organ System/ Recommendat Quality of Recomm Therapeutic Category/Drug(s) Rationale ion Evidence endation References Anticholinergics (excludes TCAs) First-generation antihistamines Highly anticholinergic; Avoid Hydroxyzin Strong Agostini 2001 (as single agent or as part of clearance reduced with e and Boustani 2007 combination products) advanced age, and promethazi Guaiana 2010 Brompheniramine tolerance develops ne: high; Han 2001 Carbinoxamine when used as hypnotic; All others: Rudolph 2008 Chlorpheniramine increased risk of moderate Clemastine confusion, dry mouth, Cyproheptadine constipation, and other Dexbrompheniramine anticholinergic Dexchlorpheniramine effects/toxicity. Diphenhydramine (oral) Doxylamine Use of diphenhydramine in Hydroxyzine special situations such Promethazine as acute treatment of Triprolidine severe allergic reaction may be appropriate. Antiparkinson agents Not recommended for Avoid Moderate Strong Rudolph 2008 Benztropine (oral) prevention of Trihexyphenidyl extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease. Antispasmodics Highly anticholinergic, Avoid Moderate Strong Lechevallier- Belladonna alkaloids uncertain except in Michel 2005 Clidinium-chlordiazepoxide effectiveness. short-term Rudolph 2008 Dicyclomine palliative Hyoscyamine care to Propantheline decrease Scopolamine oral secretions. Antithrombotics Dipyridamole, oral short-acting* May
    [Show full text]
  • Drug Class Review Beta Adrenergic Blockers
    Drug Class Review Beta Adrenergic Blockers Final Report Update 4 July 2009 Update 3: September 2007 Update 2: May 2005 Update 1: September 2004 Original Report: September 2003 The literature on this topic is scanned periodically. The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Mark Helfand, MD, MPH Kim Peterson, MS Vivian Christensen, PhD Tracy Dana, MLS Sujata Thakurta, MPA:HA Drug Effectiveness Review Project Marian McDonagh, PharmD, Principal Investigator Oregon Evidence-based Practice Center Mark Helfand, MD, MPH, Director Oregon Health & Science University Copyright © 2009 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 4 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION .......................................................................................................................... 6 Purpose and Limitations of Evidence Reports........................................................................................ 8 Scope and Key Questions .................................................................................................................... 10 METHODS.................................................................................................................................
    [Show full text]
  • Stimulatory Action of Telmisartan, an Antagonist of Angiotensin II Receptor, on Voltage-Gated Na+ Current: Experimental and Theoretical Studies
    Chinese Journal of Physiology 61(1): 1-13, 2018 1 DOI: 10.4077/CJP.2018.BAG516 Stimulatory Action of Telmisartan, an Antagonist of Angiotensin II Receptor, on Voltage-Gated Na+ Current: Experimental and Theoretical Studies Tzu-Tung Chang, Chia-Jung Yang, Yu-Chi Lee, and Sheng-Nan Wu Department of Physiology, National Cheng Kung University Medical College, Tainan 70101, Taiwan, Republic of China Abstract Telmisartan (Tel) is recognized as a non-peptide blocker of AT1R. Whether this agent has any direct effects on ion currents remains unexplored. In whole-cell current recordings, addition of Tel + increased the peak amplitude of voltage-gated Na (NaV) current (INa) accompanied by the increased time constant of INa inactivation in differentiated NSC-34 motor neuron-like cells. Tel-stimulated INa in these cells is unlinked to either blockade of AT1R or activation of peroxisome proliferator-activated receptor gamma (PPAR-γ). In order to explore how this compound affects the amplitude and kinetics of INa in neurons, a Hodgkin-Huxley-based (HH-based) model designed to mimic effect of Tel on the functional activities of neurons was computationally created in this study. In this framework, the parameter for h inactivation gating variable, which was changed in a stepwise fashion, was implemented + + to predict changes in membrane potentials (V) as a function of maximal Na (GNa), K conductance (GK), or both. As inactivation time course of INa was increased, the bifurcation point of V versus GNa became lower, and the range between subcritical and supercritical values at the bifurcation of V versus GK correspondingly became larger.
    [Show full text]
  • Alpha^ and Beta^Blocking Agents: Pharmacology and Properties
    CURRENT DRUG THERAPY DONALD G. VIDT, MD AND ALAN BAKST, PharmD, EDITORS Alpha^ and beta^blocking agents: pharmacology and properties PROFESSOR B.N.C. PRICHARD • Adrenergic receptors have been separated into alpha and beta groups, which have then been further subdivided. Agents have been developed that block each type of receptor with varying degrees of specificity between the sub-types, leading to differences in pharmacodynamic profile. A more recent innovation has been the development of multiple action beta-blocking drugs, ie, those not only blocking the beta receptors but also posessing a peripheral vasodilator effect that may be due to alpha blockade, beta-2 stimulation, or a vasodilator action independent of either alpha or beta receptors. • INDEX TERMS: ALPHA BLOCKERS; BETA BLOCKERS; HYPERTENSION • CLEVE CLIN ] MED 1991; 58:33 7-350 HE CONCEPT that binding of Rosenblueth suggested that a transmitter released at catecholamines to receptors leads to differ- sympathetic nerve endings produced either inhibitory ing responses was first described by Langley, or excitatory responses as a result of combination with who in 1905 noted that a cell may make sympathin I or sympathin E at the receptor.3 Tmotor or inhibitory substances or both, and that "the The current classification of alpha and beta respon- effect of a nerve impulse depends upon the proportion ses is based on the classic work of Ahlquist,4 who of the two kinds of receptive substance which is af- studied six sympathomimetic amines and found two fected by the impulse."1 In 1906, Dale reported that patterns of reactivity. One group of actions, mediated ergot blocked the excitatory but not the inhibitory ac- by what were termed "alpha receptors," were principally tions of adrenaline.2 In 1933, Cannon and excitatory.
    [Show full text]
  • Download Leaflet View the Patient Leaflet in PDF Format
    Package leaflet: Information for the patient Fosinopril Sodium 10 mg Tablets Fosinopril Sodium 20 mg Tablets Fosinopril sodium Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Fosinopril is and what it is used for 2. What you need to know before you take Fosinopril 3. How to take Fosinopril 4. Possible side effects 5. How to store Fosinopril 6. Contents of the pack and other information. 1. What Fosinopril is and what is it used for Fosinopril belongs to the class of medicines called Angiotensin Converting Enzyme (ACE) inhibitors that act on the heart and blood vessels. You may have been given Fosinopril to: • lower your blood pressure if it is too high (a condition called hypertension) • help your heart pump blood around your body if you have a condition known as heart failure and are also being treated with diuretics (medicines which help to remove excess fluid from the body). 2. What you need to know before you take Fosinopril Do not take Fosinopril: • if you are allergic to fosinopril or any other ACE inhibitor, or any of the other ingredients of this medicine (listed in section 6).
    [Show full text]
  • M2021: Pharmacogenetic Testing
    Pharmacogenetic Testing Policy Number: AHS – M2021 – Pharmacogenetic Prior Policy Name and Number, as applicable: Testing • M2021 – Cytochrome P450 Initial Presentation Date: 06/16/2021 Revision Date: N/A I. Policy Description Pharmacogenetics is defined as the study of variability in drug response due to heredity (Nebert, 1999). Cytochrome (CYP) P450 enzymes are a class of enzymes essential in the synthesis and breakdown metabolism of various molecules and chemicals. Found primarily in the liver, these enzymes are also essential for the metabolism of many medications. CYP P450 are essential to produce many biochemical building blocks, such as cholesterol, fatty acids, and bile acids. Additional cytochrome P450 are involved in the metabolism of drugs, carcinogens, and internal substances, such as toxins formed within cells. Mutations in CYP P450 genes can result in the inability to properly metabolize medications and other substances, leading to increased levels of toxic substances in the body. Approximately 58 CYP genes are in humans (Bains, 2013; Tantisira & Weiss, 2019). Thiopurine methyltransferase (TPMT) is an enzyme that methylates azathioprine, mercaptopurine and thioguanine into active thioguanine nucleotide metabolites. Azathioprine and mercaptopurine are used for treatment of nonmalignant immunologic disorders; mercaptopurine is used for treatment of lymphoid malignancies; and thioguanine is used for treatment of myeloid leukemias (Relling et al., 2011). Dihydropyrimidine dehydrogenase (DPD), encoded by the gene DPYD, is a rate-limiting enzyme responsible for fluoropyrimidine catabolism. The fluoropyrimidines (5-fluorouracil and capecitabine) are drugs used in the treatment of solid tumors, such as colorectal, breast, and aerodigestive tract tumors (Amstutz et al., 2018). A variety of cell surface proteins, such as antigen-presenting molecules and other proteins, are encoded by the human leukocyte antigen genes (HLAs).
    [Show full text]
  • ALLHAT Protocol, Can Enter the Trial at the Discretion of the Principal Investigator Or His/Her Designee
    Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Protocol Revised: March 1995 May 1995 April 1998 April 2000 April 2000 Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Protocol Table of Contents Page I. Overview............................................................................................................................ 2 II. Background........................................................................................................................ 4 III. Hypotheses and Study Power ........................................................................................... 10 IV. Eligibility and Exclusions................................................................................................. 13 V. Recruitment....................................................................................................................... 17 VI. Antihypertensive Intervention .......................................................................................... 22 VII. Cholesterol-Lowering Intervention................................................................................... 26 VIII. Laboratory Measurements ................................................................................................ 28 IX. Outcome Measurements.................................................................................................... 30 X. Study Organization ..........................................................................................................
    [Show full text]
  • Accupril® (Quinapril Hydrochloride Tablets)
    Accupril® (Quinapril Hydrochloride Tablets) WARNING: FETAL TOXICITY When pregnancy is detected, discontinue ACCUPRIL as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See Warnings: Fetal Toxicity DESCRIPTION ACCUPRIL® (quinapril hydrochloride) is the hydrochloride salt of quinapril, the ethyl ester of a non-sulfhydryl, angiotensin-converting enzyme (ACE) inhibitor, quinaprilat. Quinapril hydrochloride is chemically described as [3S-[2[R*(R*)], 3R*]]-2-[2-[[1- (ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3- isoquinolinecarboxylic acid, monohydrochloride. Its empirical formula is C25H30N2O5 •HCl and its structural formula is: Quinapril hydrochloride is a white to off-white amorphous powder that is freely soluble in aqueous solvents. ACCUPRIL tablets contain 5 mg, 10 mg, 20 mg, or 40 mg of quinapril for oral administration. Each tablet also contains candelilla wax, crospovidone, gelatin, lactose, magnesium carbonate, magnesium stearate, synthetic red iron oxide, and titanium dioxide. CLINICAL PHARMACOLOGY Mechanism of Action: Quinapril is deesterified to the principal metabolite, quinaprilat, which is an inhibitor of ACE activity in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor, angiotensin II. The effect of quinapril in hypertension and in congestive heart failure (CHF) appears to result primarily from the inhibition of circulating and tissue ACE activity, thereby reducing angiotensin II formation. Quinapril inhibits the elevation in blood pressure caused by intravenously administered angiotensin I, but has no effect on the pressor response to angiotensin II, norepinephrine or epinephrine. Angiotensin II also stimulates the secretion of aldosterone from the adrenal cortex, thereby facilitating renal sodium and fluid reabsorption.
    [Show full text]
  • Quinapril, an ACE Inhibitor, Reduces Markers of Oxidative Stress in the Metabolic Syndrome
    Metabolic Syndrome/Insulin Resistance Syndrome/Pre-Diabetes ORIGINAL ARTICLE Quinapril, an ACE Inhibitor, Reduces Markers of Oxidative Stress in the Metabolic Syndrome 1 3 BOBBY V. KHAN, MD, PHD W. CRAIG HOOPER, PHD ing the link between inflammation, met- 1 1 SRIKANTH SOLA, MD REKHA G. MENON, MD abolic disorders, and cardiovascular 1 1 WRIGHT B. LAUTEN, BS STAMATIOS LERAKIS, MD 2 1 disease (5,6). Chronic inflammation and RAMA NATARAJAN, PHD TAREK HELMY, MD an abnormal pro-oxidant state are both found in the metabolic syndrome and may play a role in its pathogenesis (7,8). The renin-angiotensin system (RAS) plays a central role in the pathogenesis of OBJECTIVE — Patients with the metabolic syndrome often have abnormal levels of proin- atherosclerosis-related diseases. Angio- flammatory and pro-oxidative mechanisms within their vasculature. We sought to determine tensin II, the central molecule in the RAS, whether the ACE inhibitor quinapril regulates markers of oxidative stress in the metabolic syndrome. has multiple effects on inflammation, ox- idation, atherosclerotic plaque initiation, RESEARCH DESIGN AND METHODS — Forty patients with the metabolic syndrome and progression (9). In the present study, were randomized in a double-blind manner to either the ACE inhibitor quinapril (20 mg/day) or we determine potential mechanisms by matching placebo for 4 weeks. Serum markers of vascular oxidative stress were measured. which the administration of the ACE in- hibitor quinapril regulates mechanisms of RESULTS — After 4 weeks of therapy, serum 8-isoprostane was reduced by 12% in the oxidative stress in subjects with the met- Ϯ Ϯ quinapril group when compared with placebo (quinapril, 46.7 1.0; placebo, 52.7 0.9 abolic syndrome.
    [Show full text]
  • Supporting Information a Analysed Substances
    Electronic Supplementary Material (ESI) for Analyst. This journal is © The Royal Society of Chemistry 2020 List of contents: Tab. A1 Detailed list and classification of analysed substances. Tab. A2 List of selected MS/MS parameters for the analytes. Tab. A1 Detailed list and classification of analysed substances. drug of therapeutic doping agent analytical standard substance abuse drug (WADA class)* supplier (+\-)-amphetamine ✓ ✓ S6 stimulants LGC (+\-)-methamphetamine ✓ S6 stimulants LGC (+\-)-3,4-methylenedioxymethamphetamine (MDMA) ✓ S6 stimulants LGC methylhexanamine (4-methylhexan-2-amine, DMAA) S6 stimulants Sigma cocaine ✓ ✓ S6 stimulants LGC methylphenidate ✓ ✓ S6 stimulants LGC nikethamide (N,N-diethylnicotinamide) ✓ S6 stimulants Aldrich strychnine S6 stimulants Sigma (-)-Δ9-tetrahydrocannabinol (THC) ✓ ✓ S8 cannabinoids LGC (-)-11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) S8 cannabinoids LGC morphine ✓ ✓ S7 narcotics LGC heroin (diacetylmorphine) ✓ ✓ S7 narcotics LGC hydrocodone ✓ ✓ Cerillant® oxycodone ✓ ✓ S7 narcotics LGC (+\-)-methadone ✓ ✓ S7 narcotics Cerillant® buprenorphine ✓ ✓ S7 narcotics Cerillant® fentanyl ✓ ✓ S7 narcotics LGC ketamine ✓ ✓ LGC phencyclidine (PCP) ✓ S0 non-approved substances LGC lysergic acid diethylamide (LSD) ✓ S0 non-approved substances LGC psilocybin ✓ S0 non-approved substances Cerillant® alprazolam ✓ ✓ LGC clonazepam ✓ ✓ Cerillant® flunitrazepam ✓ ✓ LGC zolpidem ✓ ✓ LGC VETRANAL™ boldenone (Δ1-testosterone / 1-dehydrotestosterone) ✓ S1 anabolic agents (Sigma-Aldrich)
    [Show full text]
  • Benign Prostatic Hyperplasia (BPH) Treatments Review 10/05/2009
    Benign Prostatic Hyperplasia (BPH) Treatments Review 10/05/2009 Copyright © 2004 - 2009 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 5181 Natorp Blvd., Suite 205 Mason, Ohio 45040 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein,
    [Show full text]
  • Angiotensin-Converting Enzyme Inhibition but Not Angiotensin II Receptor Blockade Regulates Matrix Metalloproteinase Activity in Patients with Glomerulonephritis
    J Am Soc Nephrol 14: 2861–2872, 2003 Angiotensin-Converting Enzyme Inhibition but not Angiotensin II Receptor Blockade Regulates Matrix Metalloproteinase Activity in Patients with Glomerulonephritis NADE` GE LODS,* PAOLO FERRARI,* FELIX J. FREY,* ANDREAS KAPPELER,† CELINE BERTHIER,* BRUNO VOGT,* and HANS-PETER MARTI* *Division of Nephrology and Hypertension, Inselspital Bern, Bern, Switzerland; and †Institute of Pathology, University of Bern, Bern, Switzerland Abstract. Equivalent long-term effects on the kidney are attrib- periods of 4 wk each without therapy. Untreated patients with uted to angiotensin-converting enzyme inhibitors (ACEI) and glomerulonephritis displayed distinctively higher serum levels angiotensin II type 1 receptor blockers (ARB). Nevertheless, it of MMP-2 but much lower MMP-1/-8/-9 concentrations com- is unknown to which degree effects of these compounds on pared with healthy control subjects. Immunohistology of individual inflammatory mediators, including matrix metallo- MMP-2 and MMP-9 in kidney biopsy specimen was accord- proteinases (MMP), are comparable. On the basis of structural ingly. However, these patients excreted higher amounts of and functional differences, it was hypothesized that ACEI and MMP-2 and MMP-9 in urine than healthy control subjects, ARB differentially regulate MMP activity. In a randomized, possibly reflecting ongoing glomerular inflammation. In pa- prospective crossover trial, the effect of an ACEI (fosinopril; tients with glomerulonephritis, ACEI significantly reduced 20 mg/d) and of an ARB (irbesartan; 150 mg/d) on MMP overall MMP serum activity to 25%, whereas ARB did not activity was evaluated. Ten hypertensive patients with glomer- show any effect. Activities of MMP-1/-2/-8/-9 were also sig- ulonephritis and normal or mildly reduced creatinine clearance nificantly inhibited by fosinopril but not by irbesartan.
    [Show full text]